Business Context and Reporting Period
Company: Black Diamond Therapeutics, Inc. (BDTX)
Filing Type: Form 8-K (Current Report)
Date of Report: December 3, 2025
Context: The filing reports preliminary Phase 2 clinical data for the company's lead asset, silevertinib, in non-small cell lung cancer (NSCLC) and outlines plans for a Phase 2 trial in glioblastoma (GBM). The report also includes updated financial guidance regarding cash runway.
Key Financial Metrics
Cash Position: Approximately $135.5 million in cash, cash equivalents, and investments as of September 30, 2025.
Revenue/Profit: Not reported in this filing (Company is in clinical development stage).
Debt/Liquidity: No specific debt figures provided; liquidity is defined by the cash balance mentioned above.
Material Changes and Clinical Updates
Silevertinib Phase 2 in 1L NSCLC (Non-Classical EGFR Mutations)
- Study Population: 43 frontline patients with 35 distinct non-classical EGFR mutations; 16 patients had brain metastases.
- Efficacy Data (Data Cutoff: Nov 3, 2025):
- Objective Response Rate (ORR): 60% (25 partial responses, 1 complete response).
- CNS ORR: 86%.
- Disease Control Rate: 91%.
- Duration of Treatment: 29 patients remain on therapy; longest ongoing treatment exceeds 19 months.
- Safety: No new safety signals. Common adverse events include rash, stomatitis, diarrhea, and paronychia, managed with standard care.
GBM Program Update
- Plan: Initiate a randomized Phase 2 trial in newly diagnosed GBM patients in the first half of 2026.
- Design: Approximately 150 patients randomized to temozolomide (control) vs. silevertinib + temozolomide.
- Target Population: Initial focus on EGFRvIII-positive, unmethylated patients.
- Timeline: Preliminary data expected in 2028.
Guidance, Outlook, and Risks
Updated Financial Guidance
Management updated its cash runway projection. The $135.5 million cash balance as of September 30, 2025, is now expected to fund anticipated operating expenses and capital expenditures into the second half of 2028.
Assumptions: This guidance assumes the Company funds the Phase 2 GBM trial internally and that a potential partner funds the pivotal development of silevertinib in NSCLC.
Outlook and Next Steps
- NSCLC Data Presentation: Updated results (including DOR and PFS for recurrent and frontline settings) expected at a medical meeting in Q2 2026.
- Partnerships: The Company continues to explore partnerships to advance silevertinib into pivotal development for NSCLC.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks include the uncertainty of clinical trial outcomes, the timing of regulatory feedback, the ability to secure a partnership for NSCLC pivotal development, and the accuracy of the cash runway projection.
Investor Verification Checklist
- Verify the specific assumptions regarding the "potential partner" funding pivotal NSCLC development, as the cash runway to late 2028 depends on this external funding.
- Confirm the enrollment criteria and statistical power of the planned GBM Phase 2 trial (150 patients) to assess the robustness of the 2028 data timeline.
- Monitor the Q2 2026 medical meeting for updated NSCLC data, specifically Progression-Free Survival (PFS) and Duration of Response (DOR), which were not detailed in this preliminary release.
- Review the safety profile of silevertinib in the context of the 19+ month ongoing treatment duration to assess long-term tolerability.